Technology

Scientific Data

Based on published literature and extensive research that we conducted on symptomatic and asymptomatic patients and a variety of pulmonary upper tract diseases and infection, Breath of Health has been able to identify the specific COVID19 markers. We filtered all additional markers that were present due to other conditions, and background diseases such as diabetes etc.  By cross-referencing and analysis of the data, we are able to identify several wavelengths in the FTIR that are the most important for identification of a COVID19 Infection.

Clinical Research

Clinical research is an ongoing effort at Breath of Health.

Breath of Health is currently conducting clinical trials, which have been approved by the Ministry of Health at Shiba Tel Hashomer and Hadassah Hospitals. Other research and studies are being conducted in other world-renowned medical centers around the globe

With our fixed algorithm, our mid-term results show that we have achieved a correlation of 96.33%.

We were also able to achieve accurate correlation to the CT (cycle threshold) value of the subjects that tested positive to COVID19.

The points on the chart represent the BOH calculations based on FTIR readings and correlated to a central line of the actual CT readings of these test results.

The points on the chart represent the BOH calculations based on FTIR readings and correlated to a central line of the actual CT readings of these test results.

By cross-referencing and analysis of the data, we were able to identify several wavelengths in the FTIR that are the most important for identification of a COVID19 Infection.

We chose to use the FTIR (Fourier-transform infrared spectroscopy) as our analytic system because of its availability, sensitivity, mobility and simplicity of operation thus adding another limiting factor to our choice of markers, to markers that are easily detectable by the FTIR.

Our algorithm has achieved a repeatable and stable correlation of 96.33% compared to GeneXpert Systems and NeuMoDx Molecular, Inc. PCR’s positive and negative results. We were also able to achieve accurate correlation to the CT (cycle threshold) value of the subjects that tested positive to COVID19.

There are many advantages with analyzing breath and OCs, which include the following: 

Non invasive and less strenuous sampling for subjects

Unlimited samples of breath gas allowing the collection of many samples per day

Free from biological and cellular material

Direct access to the lungs and indirect access to the systemic circulation

COVID19 the Diagnostic Challenge

The symptoms of COVID19 can resemble those of many other Diseases, making diagnostic tests essential.

Testing for the virus RNA, cannot determine whether someone has recovered; potentially miss the virus if in low levels in a patient.

Tests for antibodies or immune response cannot confirm the presence of Virus and different people can have different antibody responses to COVID19.

Advantages

Z

Takes 45 seconds

Z

Low Cost Test

Z

Contains AI algorithm for maximum accuracy

Z

Diagnoses Symptomatic and Asymptomatic patients

Z

Open API – connects to any system, Provides reports

Future Challenges to Address

Early diagnosis of cancer results in improved survival compared to diagnosis with more advanced disease.

Extensive efforts have been completed to look for AD biomarkers by measuring gene expression, protein or lipid analytes in blood samples, However, consistent or widely accepted results have not been achieved to date.

Current imaging modalities and tumor markers are much better suited to detection of recurrences of malignancies previously treated and in remission than they are to primary screening for cancer.

It is well recognized that the identification of AD in its early, pre symptomatic stages, to allow the commencement of therapeutic strategies to halt or slow disease progression, would be greatly beneficial.

Early diagnosis of cancer results in improved survival compared to diagnosis with more advanced disease.

Extensive efforts have been completed to look for AD biomarkers by measuring gene expression, protein or lipid analytes in blood samples, However, consistent or widely accepted results have not been achieved to date.

Current imaging modalities and tumor markers are much better suited to detection of recurrences of malignancies previously treated and in remission than they are to primary screening for cancer.

It is well recognized that the identification of AD in its early, pre symptomatic stages, to allow the commencement of therapeutic strategies to halt or slow disease progression, would be greatly beneficial.

Early detection of viral infection is crucial in a pandemic situation most existing methods based PCR, Serological tests and other tests are only effective after a few days after infection.

Early detection of viral infection is crucial in a pandemic situation most existing methods based PCR, Serological tests and other tests are only effective after a few days after infection.